GenSight Biologics Issues Warrants in EUR 1 Million Fundraising
Bitget2026/10/16 16:00- GenSight Biologics completed its EUR 1 million fundraising, announced October 8, 2026, issuing shares and warrants.
- The issuance included 11,940,300 pre-funded warrants exercisable for 11,940,300 additional ordinary shares.
- A further 14,537,704 investor warrants carry rights to subscribe for 7,268,852 additional ordinary shares.
- The fundraising also issued 2,597,404 ordinary shares, admitted to trading on Euronext Paris on October 12, 2026.
- Neither the pre-funded warrants nor the investor warrants will be admitted to trading on any exchange.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
